The potential for HIV fusion inhibition.
In recent years, exciting developments in the understanding of the multi-step HIV-1 entry process have revealed potential approaches for therapeutic intervention that will compensate for the early disappointments of the soluble CD4 antigen approach. Although details of the HIV-1 fusion process are clearly complex, the proof-of-concept in the clinic provided by T-20 gives high hopes that new generation inhibitors of HIV fusion will be developed. This review highlights novel drug discovery technologies that are being employed in the search for such inhibitors.
Cammack
N
N
Department of Virology, Roche Discovery, Welwyn Garden City, Hertfordshire, UK. nick.cammack@roche.com
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000187:drug effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide